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Dear Editor,
Recent studies have indicated that fungal co-infections 
have a major impact on the morbidity and mortality of 
patients with COVID-19. In these patients, the excessive 
production of inflammatory cytokines and the reduction 
in CD4 + T and CD8 + T cell count entails susceptibility to 
fungal infections.1 In addition to impaired cell-mediated 
immunity, comorbidities and immunosuppressive 
medications have a significant role in the development 
of fungal infections and have serious impacts on clinical 
outcomes.1-3
Fungal infections of the central nervous system 
(CNS) are presented in different clinical syndromes and 
compared to other CNS infections, have a higher risk 
of morbidity and mortality.4,5 In healthy individuals, 
CNS has functional and anatomical barriers to provide 
resistance against fungal infections and T lymphocytes 
play a key role in the immune surveillance of CNS.4 
Common agents responsible for CNS fungal infections 
are mucormycete, Cryptococcus, Aspergillus, and Candida 
species.5 Certain host factors make patients susceptible 
to the development of a specific etiological agent.5 
CNS infections caused by Cryptococcus, Aspergillus, 
and Candida species are associated with impaired cell 
mediated immunity and corticosteroids. In addition to 
these factors, hyperglycaemia makes patients vulnerable 
to CNS mucormycosis development.5,6 In some patients, 
these agents are able to affect the CNS by direct spread 
from paranasal sinuses, orbits, and retro-pharyngeal 
area. Furthermore, particularly in immunocompromised 
patients, the inhalation of aerosolized fungi initiates 
infection in the lung, possibly resulting in hematogenous 
spread to CNS.4,5 During the COVID-19 pandemic, 
fungal co-infections have significantly increased and 
common agents responsible for fungal infections 
are from Aspergillus and Candida genera.7 Patients 
with impaired immune system are highly exposed to 
CNS abscesses in the presence of invasive pulmonary 
aspergillosis and disseminated candidiasis, which are 
the two most prevalent fungal co-infections reported 
in patients with COVID-19.5,7,8 Recently, CNS fungal 
infections are emerging in patients with COVID-19 with 
mucormycetes and Cryptococcus species.9-11 Generally, 
CNS Cryptococcal infections presented with meningitis 
and meningoencephalitis in immunocompromised 
setting and in patients without any history of organ 
transplant or acquired immunodeficiency syndrome 
(AIDS) are associated with poorer prognosis.4,5 Common 
presentation of mucormycosis is rhino-orbital-cerebral 
invasion and, in absence of proper treatment infection, 
may result in infarction and necrosis of host tissues.5 
Because of COVID-19, various clinical presentations, such 
as neurological complications and fungal co-infections 
might be missed or misdiagnosed.7,12 In addition to the 
direct effect of COVID-19 on immune system, high-
dose corticosteroids used in COVID-19 therapeutic 
regimen, past history of immunodeficiencies, steroid 
induced hyperglycemia, and diabetes mellitus make 
COVID-19 patients highly vulnerable to the development 
of CNS fungal infections.4,5,13,14 Taken together, early 
diagnosis, appropriate antifungal therapy, controlling 
the underlying predisposing factors and, in some cases, 
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surgical intervention are crucial for reducing the high 
mortality rates of CNS fungal infections (Table 1).
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